Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31354776 | 0.85 | CA12 (0.46) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL8757145 | 0.85 | MAPT (0.45) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL16702240 | 0.82 | GSTP1 (0.49) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL16702882 | 0.80 | ALDH1A1 (0.46) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL16712939 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL16702465 | 0.79 | PDE7A (0.55) | ALDH1A1HTTKMT2AMAPTMEN1 | |
| SCHEMBL8568179 | 0.79 | ALDH1A1 (0.53) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL16702471 | 0.78 | HASPIN (0.45) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL16702310 | 0.77 | ALDH1A1 (0.39) | ALDH1A1HTTRAB9AKMT2AMAPT | |
| SCHEMBL16702722 | 0.77 | ALDH1A1 (0.43) | ALDH1A1HTTRAB9AKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542723-B1 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN INC (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1542723-A4 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN INC (US) | 2009-02-11 | — | — | EP | disclosed |
| US-6913748-B2 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1542723-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | Immunogen, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004016801-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | CD44, ABCG2, EPCAM | ALDH1A1 1402/4885HTT 3885/4885RAB9A 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.